United States - English - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - mesalamine (unii: 4q81i59gxc) (mesalamine - unii:4q81i59gxc) - mesalamine 250 mg - pentasa is indicated for the induction of remission and for the treatment of adult patients with mildly to moderately active ulcerative colitis. pentasa is contraindicated in patients with known or suspected hypersensitivity to salicylates, aminosalicylates, or any components of this medication.

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - mesalamine (unii: 4q81i59gxc) (mesalamine - unii:4q81i59gxc) - mesalamine 250 mg - pentasa is indicated for the induction of remission and for the treatment of patients with mildly to moderately active ulcerative colitis. pentasa is contraindicated in patients who have demonstrated hypersensitivity to mesalamine, any other components of this medication, or salicylates.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - mesalazine, quantity: 1 g - tablet, modified release - excipient ingredients: magnesium stearate; purified talc; ethylcellulose; povidone; microcrystalline cellulose - treatment of mild to moderate ulcerative colitis and crohn's disease and maintenance of remission.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - mesalazine, quantity: 500 mg - tablet, modified release - excipient ingredients: purified talc; ethylcellulose; povidone; microcrystalline cellulose; magnesium stearate - treatment of mild to moderate ulcerative colitis and crohn's disease and maintenance of remission.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - mesalazine, quantity: 4 g - granules, modified release - excipient ingredients: povidone; ethylcellulose - treatment of mild to moderate ulcerative colitis and crohn's disease and maintenance of remission.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - mesalazine, quantity: 2 g - granules, modified release - excipient ingredients: povidone; ethylcellulose - treatment of mild to moderate ulcerative colitis and crohn's disease and maintenance of remission.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - mesalazine, quantity: 1 g - granules, modified release - excipient ingredients: ethylcellulose; povidone - treatment of mild to moderate ulcerative colitis and crohn's disease and maintenance of remission.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - mesalazine, quantity: 1000 mg - suppository, compressed - excipient ingredients: purified talc; povidone; macrogol 6000; magnesium stearate - treatment of ulcerative procitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - mesalazine, quantity: 1000 mg - enema - excipient ingredients: disodium edetate; sodium acetate; purified water; sodium metabisulfite; hydrochloric acid - for the treatment of ulcerative proctosigmoiditis and/or treatment of left-sided ulcerative colitis.

United States - English - NLM (National Library of Medicine)

carilion materials management - mesalamine (unii: 4q81i59gxc) (mesalamine - unii:4q81i59gxc) - mesalamine 250 mg - pentasa is indicated for the induction of remission and for the treatment of patients with mildly to moderately active ulcerative colitis. pentasa is contraindicated in patients who have demonstrated hypersensitivity to mesalamine, any other components of this medication, or salicylates.